Clinical trials: Cyclophosphamide
Breast Cancer
DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
Our study is a prospective, non-inferior, randomized phase II clinical trial, to compare the efficacy and safety profiles of DA versus DAC as adjuvant chemotherapy regimens for early-stage breast cancer patients.
- Trial name
- NCT02838225
- Testing
- Docetaxel, Doxorubicin, Docetaxel, Doxorubicin, Cyclophosphamide
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
The aim of the study is to estimate the effect of preoperative gefitinib on the complete pathological response rate in primary estrogen receptor negative breast cancer at the time of surgery.
- Trial name
- NCT00239343
- Testing
- gefitinib
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 160 people
- Sponsor
- AstraZeneca
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and and Baricitinib in children and young adults with hematoloblastosis after myeloablative conditioning…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma
- Trial name
- NCT06475820
- Testing
- Baricitinib
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Breast Cancer
Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, docetaxel, and S-1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00994968
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Yonsei University
DHL, THL
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation.
- Conditions
- DHL, THL, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- NCT07552324
- Testing
- CL-Pola-R-CHP
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Sarcoma, Melanoma
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Background: A tumor cell vaccine is an experimental cancer treatment. Cancer cells are collected from a patient and then used to develop a vaccine.
- Conditions
- Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancy
- Trial name
- NCT01341496
- Testing
- Epigenetically Modified Autologous Tumor, Cyclophosphamide, Celecoxib
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen
Recently, there has been a rising trend of delaying childbearing and hence more women are diagnosed with breast cancer before completing their families.
- Trial name
- TRIUMPH (NCT02053597)
- Testing
- Doxorubicin, paclitaxel
- Where
- 4 sites in Belgium
- Sponsor
- Jules Bordet Institute
DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
This is a single-arm, open-label, multicenter clinical study evaluating the efficacy and safety of pirtobrutinib combined with Pola-R-CHP in previously untreated Non-GCB DLBCL.
- Trial name
- NCT07744724
- Testing
- Pirtobrutinib+Pola-R-CHP
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Changzhou No.2 People's Hospital
CMV Infection or Reactivation After Allogenic HSCT
The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen
The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant…
- Trial name
- CMV (NCT06362720)
- Volunteers
- 158 people
- Sponsor
- Siriraj Hospital
Advanced HCC
Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma
It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+ regulatory T cells. These cells might suppress tumor-specific immune responses.
- Trial name
- NCT00396682
- Testing
- Cyclophosphamide
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Hannover Medical School
Pancreatic Cancer
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab…
- Trial name
- NCT06782932
- Testing
- AGEN2373, Balstilimab, Cyclophosphamide
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Non-small Cell Lung Cancer (NSCLC), Metastatic Cutaneous Melanoma
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously…
- Trial name
- reICB (NCT07130032)
- Testing
- reICB regimen (NSCLC), reICB regimen (melanoma)
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- EuroCityClinic LLC
Stage IV Breast Cancer
Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide
The goal of this study is to evaluate the safety and clinical efficacy of personalized chemotherapy with low doses of cyclophosphamide administered taking into account the reparative cycle of tumor cells in participants with…
- Trial name
- NCT06361264
- Testing
- Karanahan
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- KARANAHAN
AL Amyloidosis
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD…
- Trial name
- NCT06022939
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection
- Where
- 117 sites in United States
- Volunteers
- 338 people
- Sponsor
- SWOG Cancer Research Network
Malignant Solid Tumor, Childhood Solid Tumor
Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
This is a Phase I study of the combination of three drugs: sirolimus, cyclophosphamide, and topotecan. This is the first study to evaluate the safety and clinical activity of the combination of oral sirolimus, oral…
- Trial name
- NCT01670175
- Testing
- Sirolimus, Cyclophosphamide, Topotecan
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment consisting of atezolizumab in combination with either obinutuzumab + bendamustine…
- Trial name
- NCT02596971
- Testing
- Atezolizumab, Bendamustine, Cyclophosphamide
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
MYOPATHY
Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
Myositis is a disease, believed to be due to immune cells, cells which normally protect the body, but are now attacking the muscles and other organ systems within body.
- Trial name
- NCT00278564
- Testing
- Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Northwestern University
Bone Marrow Transplant Complications, Acute Myeloid Leukemia
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
This is an open label Phase I-II study to determine the safe doses of bortezomib, sitagliptin, and PTCy (Phase I) with expansion into a phase II trial to determine efficacy in improving survival.
- Conditions
- Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes
- Trial name
- NCT05895201
- Testing
- Sitagliptin, Bortezomib, Cyclophosphamide
- Where
- United States
- Sponsor
- Indiana University
Diffuse Large B Cell Lymphoma
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
The purpose of this trial is to compare the efficacy and safety of Inotuzumab Ozogamicin in combination with R-CVP with that of R-G-CVP for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) in a population of patients not…
- Trial name
- INCA (NCT01679119)
- Testing
- Cyclophosphamide, Vincristine, Prednisolone
- Where
- 40 sites in United Kingdom
- Volunteers
- 129 people
- Sponsor
- University College, London
Nausea, Vomiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy.
- Conditions
- Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Trial name
- NCT07169851
- Testing
- LY3537021, Standard of Care Antiemetic Therapies, Background Chemotherapy
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company